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Abstract
Background: Activation of glutamate (Glu) receptors plays a key role in the pathophysiology of migraine. Both
NMDA and metabotropic Glu receptors are activated or inhibited by metabolites of the kynurenine pathway, such
as kynureninic acid (KYNA), quinolinic acid (QUINA), and xanthurenic acid (XA). In spite of the extensive research
carried out on KYNA and other kynurenine metabolites in experimental models of migraine, no studies have ever
been carried out in humans. Here, we measured all metabolites of the kynurenine pathway in the serum of patients
affected by chronic migraine (CM) and age- and gender-matched healthy controls.
Methods: We assessed serum levels of tryptophan (Trp), L-kynurenine (KYN), KYNA, anthranilic acid (ANA),
3-hydroxyanthranilic acid (3-HANA), 3-hydroxykynirenine (3-HK), XA, QUINA, and 5-hydroxyindolacetic acid
(5-HIAA) in 119 patients affected by CM (ICHD-3beta criteria) and 84 age-matched healthy subjects.
Patients with psychiatric co-morbidities, systemic inflammatory, endocrine or neurological disorders, and mental
retardation were excluded. Serum levels of all metabolites were assayed using liquid chromatography/tandem mass
spectrometry (LC-MS/MS).
Results: LC-MS/MS analysis of kynurenine metabolites showed significant reductions in the levels of KYN (−32 %),
KYNA (−25 %), 3-HK (−49 %), 3-HANA (−63 %), 5-HIAA (−36 %) and QUINA (−80 %) in the serum of the CM patients,
as compared to healthy controls. Conversely, levels of Trp, ANA and XA were significantly increased in CM patients
(+5 %, +339 % and +28 %, respectively).
Conclusions: These findings suggest that in migraine KYN is unidirectionally metabolized into ANA at expenses of
KYNA and 3-HK. The reduction in the levels of KYNA, which behaves as a competitive antagonist of the glycine site
of NMDA receptors, is consistent with the hypothesis that NMDA receptors are overactive in migraine. The increase
in XA, a putative activator of Glu2 receptors, may represent a compensatory event aimed at reinforcing endogenous
analgesic mechanisms. The large increase in the levels of ANA encourages research aimed at establishing whether
ANA has any role in the regulation of nociceptive transmission.
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Background
Among primary headache disorders, migraine is common
in clinical practice [1]. It is characterized by a natural
fluctuation between a low and a high frequency pattern
under the influence of modifiable and non-modifiable risk
factors [2]. Increased attack frequency may lead to the
so-called ‘chronic migraine’ (CM), which becomes less
responsive to both acute and prophylactic treatments.
CM is associated with significant disability and high
socioeconomic impact [3, 4], which make CM a major
public health problem [5, 6]. In spite of the increas-
ing number of drugs marketed for the treatment of
migraine, a substantial proportion of patients do not
respond to medication, and are therefore at risk for
chronicization [7].
Four not-mutually-exclusive mechanisms have been im-
plicated in the pathophysiology of migraine: (i) peripheral
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sensitization of the trigeminovascular system; (ii) central
sensitization of the caudal trigeminal nucleus and other
central nervous system (CNS) structures of the pain neur-
axis; (iii) activation of brainstem migraine generators;
and, (iv) cortical spreading depression, underlying aura
phenomenon of migraine with aura [8]. All these pro-
cesses are mediated by allostatic changes in mecha-
nisms of activity-dependent synaptic plasticity, such as
long-term potentiation (LTP) and long-term depression
(LTD). Glutamate (Glu), the major excitatory neuro-
transmitter, is involved in the induction and expression
of both LTP and LTD, and, therefore, extensive research
has focused on the role of Glutamatergic transmission in
the pathophysiology of migraine. N-methyl-D-aspartate
(NMDA) receptors, have an established role in mecha-
nisms of central sensitization [9, 10] and in the onset and
propagation of cortical spreading depression [11, 12]; in
addition, an association has been found between migraine
and polymorphisms in genes involved in the regulation
of synaptic Glu uptake and postsynaptic Glu signaling
[13–15]. Increased plasma and cerebrospinal fluid Glu
levels have been reported in patients affected by mi-
graine [16, 17], but the interpretation of these findings
is limited by the large prevalence of the metabolic pool
of Glu with respect to the neurotransmitter pool. Inves-
tigation on other endogenous ligands of Glu receptors
in patients affected by migraine is limited. The KP of
Trp metabolism generates a series of compounds that
interact with Glu receptors, and, therefore, have been
implicated in the pathophysiology of migraine [18]. The
pathway is activated by either indolamine 2,3-dioxygen-
ase (IDO) or tryptophan 2,3-dioxygenase (TDO), which
transform L-tryptophan into N-formylkynurenine. L-
kynurenine (KYN), 3-hydroxykynurenine (3-HK), kynure-
nic acid (KYNA) anthranilic acid (ANA), xanthurenic acid
(XA), 3-hydroxyanthranylic acid (3-HANA) and quinoli-
nic acid (QUINA) synthesis are shown in Fig. 1. KYNA
inhibits NMDA receptors behaving as a competitive an-
tagonist at the glycine site of the GluN1 subunit, whereas
QUINA is an orthosteric agonist at the GluN2A-D sub-
units of NMDA receptors [19]. Recent evidence suggests
that XA behaves as an endogenous activator of type-2 me-
tabotropic Glu receptors (mGlu2 receptors) [20], whereas
cinnabarinic acid is a weak orthosteric agonist of mGlu4
receptors [21].
The influence of peripherally administered KYNA or
its precursor, KYN, on the trigeminovascular system or
cortical spreading depression has been the subject of
extensive investigation, and pharmacological strategies
aimed at enhancing KYNA synthesis have been suggested
in migraine [8] (see also Discussion and References
therein).
To our knowledge, no measurements of kynurenine me-
tabolites have been performed in the plasma of patients
affected by migraine or other forms of chronic headache.
This aspect is not trivial because brain levels of IDO and
TDO are low, and peripheral L-kynurenine and 3-HK fuel
the kynurenine pathway in the CNS [19]. Here we report
the surprising finding that ANA levels are substantially
increased in the plasma of patients affected by CM, at the
expenses of all other kynurenine metabolites with the
notable exception of XA.
Methods
Patients
The protocol was carried out in accordance with the
declaration of Helsinki and the study design was reviewed
and approved by the Ethical Committee at Sapienza,
University of Rome, Sant’Andrea Hospital. All subjects
signed free informed consent for participation in the
study. All subjects were enrolled by the Regional Re-
ferral Headache Center of S. Andrea Hospital and
evaluated by two experts in headache disorders (A.N.
and P.M.). 119 patients met the ICHD-3beta criteria
for CM and were included in the CM group, and 84
healthy subjects were included in the age-matched control
group. Inclusion criteria for CM patients were: (i) age
between 18 and 75 years; (ii) patients treated with Onabo-
tulinumtoxinA for the prophylactic therapy (iii) patients
treated with triptans or any other analgesics during the
headache attacks.
Exclusion criteria were: (i) the presence of psychiatric
co-morbidities, immunological disorders, endocrine dis-
orders, neurological disorders, and mental retardation;
(ii) lifetime history of migraine (for healthy volunteers);
and (iii) the use of any drug of abuse in the last 3 months
(except cigarette smoking). Both patients in an attack
free and in a pain period were included.
Blood collection and KP measurement
Serum samples from patients and controls were collected
between 10 am and 12 am. Blood (5 ml) was sampled in
anticoagulant-free tubes and kept at room temperature for
1 h before the serum was isolated (centrifugation at
2000 g for 10 min at 20 °C).
We developed a liquid chromatography/tandem mass
spectrometry (LC-MS/MS) method for the assay of serum
levels of all kynurenine metabolites. The method allowed a
reliable detection of KYN, KYNA, ANA, 3-HANA, 3-HK,
XA, and QUINA. Levels of Trp and 5-HIAA were also
detected. Details on sample preparation, reagents, standard
solutions, chromatographic conditions, mass spectrometry
conditions, and validation parameters are reported in
Fazio et al., [20].
Statistical analysis
SPSS version 19.00 (IBM Corporation, Armonk NY,
USA) was used for data analysis. Continuous variables
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were expressed as mean standard ± deviation (SD), while
discrete variables were assigned as numbers and per-
centages. The compliance of continuous variables with
normal distribution was controlled with the Kolmogorov–
Smirnov test. Whether Healthy Controls and Cluster
Headache groups differed in terms of discrete variables
was checked through Pearson's Chi Squared test (χ2).
Since continuous variables did not comply with a normal
distribution, the Mann–Whitney U test was used for
between group comparisons. We set statistical significance
at P ≤ 0.05.
Results
Demographic characteristics of patients affected by CM
(n = 119) and age-matched healthy controls (HCs) (n = 84)
are shown in Table 1. The CM group, as expected, showed
a prevalence of female gender (72.3 %), which did not
differ from the percentage of female gender in the selected
HCs (82.1 %). Mean age was 44 and 40 years in patients
affected by CM and in HCs, respectively (see Table 1).
LC-MS/MS analysis of kynurenine metabolites showed
significant reductions in serum levels of KYN (−32 %),
KYNA (−25 %), 3-HK (−49 %), 3-HANA (−63 %), and
Fig. 1 The Kynurenine Pathway of Tryptophan metabolism. The kynurenine pathway. (1.a) Indoleamine-pyrrole 2,3-dioxygenase; (1.b) tryptophan
2,3-dioxygenase; (2) arylamine formamidase; (3) kynurenine aminotransferase; (4) kynurenine 3-hydroxylase; (5) kynureninase; (6) 3-hydroxyanthranilic
acid 3,4-dioxygenase
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QUINA (−80 %). Surprisingly, ANA levels were largely
increased (+339 %) in the serum of patients affected by
CM. XA levels were also increased in CM patients, but
to a lower extent (+28 %). We extended the analysis to
the precursor L-Trp, and the serotonin metabolite, 5-
HIAA. We found a small, but significant, increase in
Trp levels (+5 %) associated with a substantial reduction
in 5-HIAA levels in the serum of patients affected by
CM (Table 1, Fig. 2). No difference between serum levels
of any kynurenine metabolites was found between
male and female subjects in CM patients and HCs
(not shown).
Discussion
We have shown for the first time that CM is associated
with abnormalities of the kynurenine pathway, as reflected
by changes in serum levels of KYN and all downstream
metabolites. An important question in all studies in which
putative neuroactive molecules are measured in peripheral
blood is whether, and to what extent, blood levels reflect
CNS levels. It has been demonstrated that peripheral KYN
and 3-HK cross the blood–brain barrier and fuel the
KP in the CNS, where IDO and TDO activities are
constitutively low. Brain penetration is lower for other
kynurenine metabolites (reviewed by Schwarcz et al.,
[19]). Thus, we cannot exclude that changes of at
least some kynurenine metabolites we have found in
CM patients originate in the liver and other organs
rather than in the CNS. In spite of these limitations,
our data indicate that CM is associated with substan-
tial changes in the levels of kynurenine metabolites
that are not easy to explain on the basis of our classical
knowledge of the KP. In CM patients, levels of all metabo-
lites that lie downstream of KYN were largely reduced,
with the exception of ANA levels, which were dramatically
increased, and XA levels, which were increased to a much
lower extent. These findings suggest that KYN is rapidly
and unidirectionally metabolized into ANA at expenses of
KYNA and 3-HK. This is unusual, and we are not aware
of any other conditions in which a large accumulation of
ANA is associated with a reduction of most of all other
kynurenine metabolites. The large accumulation of ANA
suggests that its transformation into 3-HANA is largely
reduced in migraine. The significant increase in XA levels
found in CM patients is also difficult to explain because
the enzyme Kynurenine Aminotrasferase (KAT), which
transaminates 3-HK into XA also converts KYN into
KYNA (reviewed by Schwarcz et al., [19]), the levels of
which were reduced in CM patients. Perhaps the degrad-
ation of XA is defective in migraine. However, this
hypothesis could not be tested because of the incomplete
knowledge of XA catabolism.
We will attempt to correlate these changes to the
pathophysiology of migraine to the best of our know-
ledge. The study of kynurenine metabolites in models of
migraine has been focused on KYNA, which displays
pleiotropic actions in the CNS by inhibiting NMDA re-
ceptors and α7-nicotinic acetylcholine receptors, and
activating the GPR35 G-protein coupled receptor [22].
KAT, the enzyme that transforms KYN into KYNA, is
found in Schwann cells, macrophages, and mast cells in
the supratentorial dura mater of rats, and its activity is
reduced by stimulation of the trigeminal ganglion [23].
KYN (boosted with probenecid) or synthetic analogues
of KYNA given systemically inhibit the activation of the
caudal trigeminal nucleus in experimental animal models
of migraine [24–28]. KYN and KYNA also inhibit the
development of cortical spreading depression and the
associated changes in the permeability of the blood brain
barrier, and at least the effect of KYN is modulated by sex
hormones [22, 29, 30]. Taken together, these findings sug-
gest that KYNA has a protective role against migraine by
restraining the activation of NMDA receptors. The reduc-
tion in KYNA levels we have seen in the serum of CM
patients is consistent with the hypothesis that NMDA
receptors are overactive in migraine (see Background and
References therein).
Table 1 Serum levels of kynurenine metabolites, tryptophan,







(n = 84) (n = 119) p
Gender (F, %) 69 (82.1) 86 (72.3) 2.66
0.071
Age (years; mean ± SD) 40.4 ± 9.43 44.0 ± 11.6 4446
0.180
Trp (μg/ml) (mean ± SD) 5.00 ± 1.55 5.27 ± 1.70 4198
0.052
KYN (μg/ml) (mean ± SD) 0.34 ± 0.12 0.23 ± 0.09 2286
<0.001
KYNA (ng/ml) (mean ± SD) 3.27 ± 1.85 2.46 ± 1.29 3692
0.002
ANA (ng/ml) (mean ± SD) 2.28 ± 2.14 10.0 ± 5.92 565
<0.001
3-HK (ng/ml) (mean ± SD) 2.39 ± 3.14 1.21 ± 0.69 3498
<0.001
3-HANA (ng/ml) (mean ± SD) 9.11 ± 4.33 3.42 ± 1.40 553
<0.001
QUINA (ng/ml) (mean ± SD) 18.2 ± 12.5 3.78 ± 3.34 580
<0.001
5-HIAA (ng/ml) (mean ± SD) 32.6 ± 11.4 20.8 ± 8.16 1991
<0.001
XA (ng/ml) (mean ± SD) 1.80 ± 1.01 2.30 ± 1.52 4108
0.048
Trp tryptophan, KYN L-kynurenine, KYNA kynurenic acid, ANA anthranilic
acid, 3-HK 3-hydroxykynurenine, 3 – HANA 3-hydroxyanthranylic acid,
QUINA quinolinic acid, 5-HIAA 5-hydroxyindoleacetic acid, XA xanthurenic
acid (XA)
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Interestingly, CSF and serum KYNA levels are increased
in patients affected by schizophrenia [19, 20], a CNS
disorder characterized by a hypofunction of NMDA re-
ceptors [31]. Thus, peripheral KYNA levels might repre-
sent a reliable indicator of NMDA receptor function in
distinct CNS disorders.
One might argue that the large reduction in serum
QUINA levels we have seen in CM patients may limit
the activation of NMDA receptors in migraine because
QUINA behaves as an orthosteric NMDA receptor
agonist [32]. However, migraine is characterized by an
increased glutamatergic transmission [8, 11], and, under
these conditions, NMDA receptors may be fully acti-
vated by the high synaptic Glu levels combined with
low KYNA levels. Thus, at least in migraine, the reduc-
tion in KYNA levels might facilitate NMDA receptor
activation in spite of the simultaneous reduction in
QUINA levels.
Recent findings suggest that XA activates mGlu2 and
mGlu3 receptors [20], although XA may also indirectly
influence glutamatergic transmission by interacting with
vesicular Glu transporters [33, 34]. mGlu2 receptors
negatively modulate pain transmission, and drugs that
activate or induce mGlu2 receptors are promising candi-
dates in the experimental treatment of migraine (reviewed
by Chiechio et al., [35]). Hence, the increase in XA levels
we have found in CM patients may represent a compensa-
tory event aimed at reinforcing endogenous analgesic
mechanisms in migraine. In this particular case, the high
Glu levels may not compete with XA because mGlu2
receptors are preferentially localized in the pre-terminal
region of nerve terminals, and are therefore not accessible
to synaptically released Glu (reviewed by Nicoletti et
al., [36]).
Finally, the functional significance of the large increase
in ANA levels we have seen in CM patients is obscure.
No specific function or receptor targets for ANA have
been described to date. Our findings strongly encourage
the study of ANA in models of pain in general and of
migraine in particular.
Fig. 2 Percent changes in serum kynurenine metabolites in patients affected by CM with respect to healthy controls. Data are presented
as per cent of HC values for each metabolite. Values are means ± S.E.M. *p < 0.05 vs. healthy controls (HCs)
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Conclusions
In conclusion, we have demonstrated for the first time
that CM is associated with abnormalities of the kynure-
nine pathway metabolites. In particular, we found a re-
duction of KYNA levels with a simultaneous reduction
in QUINA levels and increase in XA and ANA levels.
KYNA reduction and QUINA increase are consistent
with the hypothesis that NMDA receptors are overactive
in migraine, and the increase in XA levels may represent
a compensatory event aimed at reinforcing endogenous
analgesic mechanisms in migraine. Since ANA specific
functions or targets are unknown, the significance of its
large increase in CM is obscure and these findings
strongly encourage the study of ANA in models of
migraine.
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